177 related articles for article (PubMed ID: 16168102)
1. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.
Li X; Lu Y; Liang K; Liu B; Fan Z
Breast Cancer Res; 2005; 7(5):R589-97. PubMed ID: 16168102
[TBL] [Abstract][Full Text] [Related]
2. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
3. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.
Qiao M; Iglehart JD; Pardee AB
Cancer Res; 2007 Jun; 67(11):5293-9. PubMed ID: 17545609
[TBL] [Abstract][Full Text] [Related]
4. PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells.
Burdick AD; Ivnitski-Steele ID; Lauer FT; Burchiel SW
Carcinogenesis; 2006 Nov; 27(11):2331-40. PubMed ID: 16774943
[TBL] [Abstract][Full Text] [Related]
5. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells.
van Nimwegen MJ; Huigsloot M; Camier A; Tijdens IB; van de Water B
Mol Pharmacol; 2006 Oct; 70(4):1330-9. PubMed ID: 16825486
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
8. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
9. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
10. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
Hua KT; Way TD; Lin JK
Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
[TBL] [Abstract][Full Text] [Related]
11. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
12. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S
Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
Singh B; Cook KR; Vincent L; Hall CS; Berry JA; Multani AS; Lucci A
J Surg Res; 2008 Jun; 147(2):240-6. PubMed ID: 18498876
[TBL] [Abstract][Full Text] [Related]
14. The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin-mediated cytotoxicity.
Lüpertz R; Chovolou Y; Unfried K; Kampkötter A; Wätjen W; Kahl R
Carcinogenesis; 2008 Nov; 29(11):2045-52. PubMed ID: 18687668
[TBL] [Abstract][Full Text] [Related]
15. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Wu CW; Lui WY
Eur J Clin Invest; 2006 Aug; 36(8):588-96. PubMed ID: 16893382
[TBL] [Abstract][Full Text] [Related]
16. Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
Wang YA; Johnson SK; Brown BL; Dobson PR
Oncol Rep; 2009 Feb; 21(2):437-42. PubMed ID: 19148520
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers.
Nakajima H; Sakaguchi K; Fujiwara I; Mizuta M; Tsuruga M; Magae J; Mizuta N
Biochem Biophys Res Commun; 2007 Apr; 356(1):260-5. PubMed ID: 17350598
[TBL] [Abstract][Full Text] [Related]
18. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.
Park CM; Park MJ; Kwak HJ; Lee HC; Kim MS; Lee SH; Park IC; Rhee CH; Hong SI
Cancer Res; 2006 Sep; 66(17):8511-9. PubMed ID: 16951163
[TBL] [Abstract][Full Text] [Related]
19. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
Knuefermann C; Lu Y; Liu B; Jin W; Liang K; Wu L; Schmidt M; Mills GB; Mendelsohn J; Fan Z
Oncogene; 2003 May; 22(21):3205-12. PubMed ID: 12761490
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells.
Zhang M; Fang X; Liu H; Guo R; Wu X; Li B; Zhu F; Ling Y; Griffith BN; Wang S; Yang D
Cancer Lett; 2007 Jul; 252(2):244-58. PubMed ID: 17293030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
